Skip to main content
Clinical Trials/NCT00141882
NCT00141882CompletedPhase 3

Memantine in Patients With Chronic Glaucoma

Allergan0 sites1,119 target enrollmentStarted: March 1, 1999Last updated:
Conditions
Drugs

Trial Snapshot

Phase
Phase 3
Status
Completed
Sponsor
Allergan
Enrollment
1,119
Primary Endpoint
Progression of glaucoma

Study Overview

Brief Summary

Randomized double-masked clinical trial of memantine in patients with glaucoma

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double

Eligibility Criteria

Ages
18 Years to 80 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Glaucoma damage on examination of visual field and optic disc
  • Good visual acuity (with glasses if needed)

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Progression of glaucoma

Secondary Outcomes

No secondary outcomes reported

Investigators

Sponsor
Allergan
Sponsor Class
Industry

Similar Trials

Related News

Memantine in Patients With Chronic Glaucoma | Clinical Trial